Ocean Biomed antibody seen able to control growth of human tumor cells with EGFR mutation

 Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations. These research findings, which may be the most important Ocean Biomedical has announced to date, generated by Ocean’s Scientific Co-founder Dr. Jack A. Elias and colleagues from Yale University and Brown University, and first published as a preprint last week in bioRxiv, are the first to uncover the role of Chitinase 3-like-1 (CHI3L1) in the pathogenesis of EGFR-mutant cancers, with potential applications not just in NSCLC, but in all EGFR-mutant cancers, including glioblastoma and colon cancer.

https://www.globenewswire.com/news-release/2023/10/03/2753594/0/en/Ocean-Biomedical-Announces-Newly-Published-Findings-Demonstrating-Ability-to-Restore-Treatment-Sensitivity-to-AstraZeneca-s-Leading-Lung-Cancer-Drug-After-Resistance-Has-Formed-and.html